プロバイオティクスと健康に関するジャーナル
オープンアクセス

概要

The Promise and Challenges of SGLT2 Inhibitors in Heart Failure Management

Arav Jain*

Heart Failure (HF) represents a global pandemic affecting over 64 million people worldwide, with rising prevalence due to an aging population and improved survival following acute cardiovascular events. Despite significant advances in pharmacological and device-based therapies over recent decades, the prognosis for patients with heart failure remains poor, with high rates of hospitalization and mortality. The persistent burden of this syndrome has driven the search for novel therapeutic approaches beyond traditional neurohormonal antagonists.